Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Paving the way

How Amgen, Sandoz IP battles may unleash a flood of Humira, Enbrel biosimilars

Amgen Inc. and the Sandoz unit of Novartis AG are charting a course that could create competitive U.S. markets for two of the biggest prizes in the biosimilars universe, AbbVie Inc.'s Humira adalimumab and Amgen's Enbrel etanercept, which together had U.S. sales of $13.4 billion in 2015.

Unanimous advisory committee endorsements for ABP 501, Amgen's version of adalimumab, and GP2015, Sandoz's etanercept, suggest the two companies have overcome the formidable scientific and regulatory hurdles to gaining the first FDA approvals for self-injectable biosimilars.

The two companies adopted regulatory strategies that went beyond FDA's minimum requirements.

To increase the chances of FDA approval and bolster the confidence of physicians and patients, Amgen gold-plated its development program by conducting a clinical trial that the agency said was unnecessary.

Sandoz, with one eye on a future application for interchangeability and the other looking to persuade physicians to switch patients from branded Enbrel to biosimilar GP2015, incorporated a switching extension in its clinical trial that the agency had not asked for and excluded from its review.

Once they have FDA approval, Amgen and Sandoz will have to bash holes through dense patent thickets, and create and execute commercial and marketing strategies suited to the new competitive landscape.

AbbVie has over 70 Humira patents that it claims will keep biosimilars off the U.S. market until 2022.

Amgen has stated that it could launch its biosimilar Humira "as soon as 2017," but the best-case scenario for launching with minimal IP risk is late 2018 or early 2019.

Sandoz hasn't provided guidance on the launch date for its etanercept, but it must win pending litigation or wait for the expiration of Amgen's Enbrel patents in 2029.

The commercial environment will be complex because AbbVie and Amgen have additional defenses against erosion of the Humira and Enbrel markets, including exploiting physician and patient skepticism about biosimilars, using discounts and rebates to undercut biosimilar pricing and adding new indications.

Marketing and support will be critically important because the products are chronically self-administered, unlike biosimilars of oncology products.

After having overcome all of these challenges, there is also a real risk the biosimilar pioneers could find themselves in a crowded, chaotic marketplace.

Amgen's and Sandoz's success in punching holes in the Humira and Enbrel IP defenses will lower the barriers to market for competitors that are poised to swarm onto the market. At that point, a Darwinian selection based on marketing prowess and manufacturing capacity and

Read the full 4130 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers